Stock 000650 RENHE PHARMACY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Renhe Pharmacy Co., Ltd.

Equities

000650

CNE000000NF8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 07/05/2024 BST 		5-day change 1st Jan Change
6.87 CNY +1.03% Intraday chart for Renhe Pharmacy Co., Ltd. +5.21% +3.62%
04-29 Renhe Pharmacy Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-26 Renhe Pharmacy Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 6,786 7,826 8,540 12,857 8,666 9,282
Enterprise Value (EV) 1 5,019 5,602 5,731 10,088 5,146 5,908
P/E ratio 13.4 x 14.7 x 13.6 x 19.4 x 15.1 x 16.2 x
Yield 1.82% 1.58% 3.28% 1.07% 3.23% -
Capitalization / Revenue 1.54 x 1.71 x 2.08 x 2.6 x 1.68 x 1.84 x
EV / Revenue 1.14 x 1.22 x 1.4 x 2.04 x 1 x 1.17 x
EV / EBITDA 6 x 6.45 x 6.74 x 10.1 x 5.2 x 5.09 x
EV / FCF 13.3 x 13.6 x 12 x 47.8 x 5.77 x 182 x
FCF Yield 7.51% 7.35% 8.36% 2.09% 17.3% 0.55%
Price to Book 2 x 2.06 x 1.68 x 2.47 x 1.51 x 1.48 x
Nbr of stocks (in thousands) 1,238,340 1,238,340 1,399,938 1,379,558 1,399,938 1,399,938
Reference price 2 5.480 6.320 6.100 9.320 6.190 6.630
Announcement Date 25/04/19 24/04/20 22/04/21 25/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 4,403 4,581 4,106 4,936 5,153 5,032
EBITDA 1 836.1 869.2 850.4 1,003 989.6 1,160
EBIT 1 746 786.4 770.7 922.5 878.8 1,025
Operating Margin 16.94% 17.17% 18.77% 18.69% 17.05% 20.37%
Earnings before Tax (EBT) 1 755.3 823.9 847.6 1,034 953.5 898.9
Net income 1 506.5 537.8 568.7 665 574.4 567.3
Net margin 11.5% 11.74% 13.85% 13.47% 11.15% 11.27%
EPS 2 0.4100 0.4300 0.4500 0.4800 0.4100 0.4100
Free Cash Flow 1 376.7 411.7 479.3 211.1 892.1 32.5
FCF margin 8.56% 8.99% 11.67% 4.28% 17.31% 0.65%
FCF Conversion (EBITDA) 45.06% 47.37% 56.36% 21.05% 90.15% 2.8%
FCF Conversion (Net income) 74.39% 76.55% 84.28% 31.74% 155.3% 5.73%
Dividend per Share 2 0.1000 0.1000 0.2000 0.1000 0.2000 -
Announcement Date 25/04/19 24/04/20 22/04/21 25/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,768 2,224 2,809 2,770 3,520 3,373
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 377 412 479 211 892 32.5
ROE (net income / shareholders' equity) 15.8% 15% 13.2% 13.8% 11.5% 9.63%
ROA (Net income/ Total Assets) 10.6% 10.2% 8.53% 8.69% 7.56% 8.5%
Assets 1 4,771 5,253 6,665 7,657 7,603 6,675
Book Value Per Share 2 2.740 3.070 3.620 3.780 4.100 4.490
Cash Flow per Share 2 1.420 1.150 1.220 1.690 2.020 1.960
Capex 1 70.1 144 218 500 221 187
Capex / Sales 1.59% 3.15% 5.31% 10.13% 4.29% 3.71%
Announcement Date 25/04/19 24/04/20 22/04/21 25/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
RENHE PHARMACY CO., LTD. Stock Renhe Pharmacy Co., Ltd.
+3.62% 1.3B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.95% 700B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.97% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.83% 330B
ABBVIE INC. Stock AbbVie Inc.
+3.54% 287B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.70% 236B
NOVARTIS AG Stock Novartis AG
+6.68% 202B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 197B
AMGEN INC. Stock Amgen Inc.
+6.70% 161B
PFIZER, INC. Stock Pfizer, Inc.
-1.81% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000650 Stock
  4. Financials Renhe Pharmacy Co., Ltd.